AT59966T - Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense. - Google Patents

Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense.

Info

Publication number
AT59966T
AT59966T AT84110118T AT84110118T AT59966T AT 59966 T AT59966 T AT 59966T AT 84110118 T AT84110118 T AT 84110118T AT 84110118 T AT84110118 T AT 84110118T AT 59966 T AT59966 T AT 59966T
Authority
AT
Austria
Prior art keywords
weaknesses
tumors
diagnosis
therapy
cellular
Prior art date
Application number
AT84110118T
Other languages
German (de)
Inventor
Udo Dr Ehrenfeld
Original Assignee
Ehrenfeld Udo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE3334751A priority Critical patent/DE3334751C2/de
Priority to DE19833336583 priority patent/DE3336583A1/en
Priority to DE19843402312 priority patent/DE3402312A1/en
Application filed by Ehrenfeld Udo filed Critical Ehrenfeld Udo
Priority to EP84110118A priority patent/EP0142641B1/en
Publication of AT59966T publication Critical patent/AT59966T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/11Aldehydes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/11Aldehydes
    • A61K31/115Formaldehyde
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/40Peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0063Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2123/00Preparations for testing in vivo
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/832Bacillus
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/872Nocardia
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/879Salmonella
AT84110118T 1983-09-26 1984-08-24 Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense. AT59966T (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE3334751A DE3334751C2 (en) 1983-09-26 1983-09-26
DE19833336583 DE3336583A1 (en) 1983-09-26 1983-10-07 Product for the diagnosis and therapy of malignant tumors
DE19843402312 DE3402312A1 (en) 1984-01-24 1984-01-24 Composition for the diagnosis and therapy of malignant tumours and for the therapy of impairment of cellular and humoral immune defences
EP84110118A EP0142641B1 (en) 1983-09-26 1984-08-24 Means and product for the diagnosis and therapy of tumours and for the treatment of weaknesses of the cellular and humoral immune system

Publications (1)

Publication Number Publication Date
AT59966T true AT59966T (en) 1991-02-15

Family

ID=27191301

Family Applications (2)

Application Number Title Priority Date Filing Date
AT84110118T AT59966T (en) 1983-09-26 1984-08-24 Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense.
AT89116295T AT159858T (en) 1983-09-26 1984-08-24 Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT89116295T AT159858T (en) 1983-09-26 1984-08-24 Agents and produce for the diagnosis and therapy of tumors and for the treatment of weaknesses of the cellular and humoral immune defense

Country Status (11)

Country Link
US (1) US5021234A (en)
EP (2) EP0350973B1 (en)
JP (1) JPH0577658B2 (en)
KR (1) KR910005408B1 (en)
AT (2) AT59966T (en)
AU (1) AU560178B2 (en)
CA (1) CA1234754A (en)
DD (1) DD222783A5 (en)
DE (2) DE3486459D1 (en)
DK (1) DK168755B1 (en)
HK (1) HK93191A (en)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU591466B2 (en) * 1984-10-22 1989-12-07 Vestar, Inc. Method of delivering micellular particles encapsulating imaging and chemotherapeutic agents to tumors in a body
DE3510795C2 (en) * 1985-03-25 1987-04-30 Udo Dr.Med. 8400 Regensburg De Ehrenfeld
EP0221821A3 (en) * 1985-11-01 1988-01-27 Centre National De La Recherche Scientifique (Cnrs) New aerosol composition for in vivo imaging and therapy
JPS63107742A (en) * 1986-05-20 1988-05-12 Wako Pure Chem Ind Ltd Novel functional liposome and its preparation
DE3621570A1 (en) * 1986-06-27 1988-01-07 Hoechst Ag Diagnostic scintigraphic representation of malignant tumors
EP0300102B1 (en) * 1987-07-21 1993-03-24 The Stolle Research And Development Corporation Improved method of obtaining immune regulatory factors by mammal immunization
FR2644059B1 (en) * 1989-03-08 1994-03-04 Fabre Medicament Pierre aerosols FOR compositions imaging, diagnosis and targeted therapy of inflammatory and tumor foci
FR2655546B1 (en) * 1989-12-11 1992-03-13 Assistance Publique A composition for intratumoral injection, and to use the pre-chemotherapy and preoperative marking, in laser therapy and thermotherapy.
US5620703A (en) * 1991-10-11 1997-04-15 Max-Delbruck-Centrum Fur Molekulare Medizin Stimulating hematopoietic activity with carboplatin or lobaplatin
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) * 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
EP1820517A3 (en) * 1995-11-17 2009-10-21 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6093697A (en) * 1994-11-07 2000-07-25 The University Of Virginia Patent Foundation Synthetic insulin mimetic substances
US6190657B1 (en) 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
CA2665133A1 (en) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine .alpha.
US6593290B1 (en) 1996-11-01 2003-07-15 Genentech, Inc. Treatment of inner ear hair cells
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
DE69841994D1 (en) 1997-05-30 2010-12-23 Human Genome Sciences Inc 32 Human secreted proteins
US6663899B2 (en) 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1012232B1 (en) * 1997-09-10 2009-10-28 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
US6080849A (en) * 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
DK2042597T3 (en) 2000-06-23 2014-08-11 Genentech Inc Compositions and procedures for diagnosis and treatment of diseases involving angiogenesis
US5906979A (en) * 1998-01-27 1999-05-25 Insmed Pharmaceuticals, Inc. Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
WO1999039729A2 (en) 1998-02-04 1999-08-12 Genentech, Inc. Use of heregulin as an epithelial cell growth factor
NZ525914A (en) 1998-03-10 2004-03-26 Genentech Inc Novel polypeptides and nucleic acids encoding the same
PT2016951E (en) 1998-03-17 2012-09-27 Genentech Inc Polypeptides homologous to vegf and bmp1
EP1982990A1 (en) 1998-03-19 2008-10-22 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
AU3501700A (en) 1999-02-26 2000-09-14 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
AU6655701A (en) 2000-04-12 2001-10-23 Human Genome Sciences Inc Albumin fusion proteins
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
AUPR546801A0 (en) 2001-06-05 2001-06-28 Commonwealth Scientific And Industrial Research Organisation Recombinant antibodies
US7767786B2 (en) 2001-08-24 2010-08-03 Neuren Pharmaceuticals Ltd. Neural regeneration peptides and methods for their use in treatment of neural injury or degeneration
CN101884784B (en) 2001-08-29 2014-03-12 杰南技术公司 Bv8 nucleic acids and polypeptides with mitogenic activity
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003057235A2 (en) 2002-01-10 2003-07-17 Imperial College Innovations Ltd Modification of feeding behavior
JP2005508324A (en) 2001-09-24 2005-03-31 インペリアル カレッジ イノベーションズ リミテッド Modification of feeding behavior
ES2321701T3 (en) 2001-10-12 2009-06-10 Schering Corporation Use of bispecific antibodies that join the fcepsilonri activation receiver and the ox2ra inhibition receiver (cd200ra) to regulate immune answers.
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
AU2002304965A1 (en) 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
AT472556T (en) 2002-12-02 2010-07-15 Amgen Fremont Inc Against the tumor nekrose factor targeted antibodies and their uses
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
MXPA05009743A (en) 2003-03-12 2006-03-09 Genentech Inc Use of bv8 and/or eg-vegf to promote hematopoiesis.
US8067544B2 (en) 2003-03-19 2011-11-29 Curagen Corporation Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
US7375076B2 (en) 2003-05-20 2008-05-20 The Regents Of The University Of Michigan Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
US7291590B2 (en) 2003-06-12 2007-11-06 Queen's University At Kingston Compositions and methods for treating atherosclerosis
KR101435167B1 (en) 2003-06-27 2014-11-04 암젠 프레몬트 인코포레이티드 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP4738337B2 (en) 2003-09-12 2011-08-03 テルシカ インコーポレーティッド Treatment of insulin-like growth factor-1 (IGF-1) deficiency
BRPI0507118A (en) * 2004-02-02 2007-06-19 Ambrix Inc modified human interferon polypeptides and their uses
US7807176B2 (en) 2004-03-19 2010-10-05 Genomidea, Inc. Polypeptide promoting vascular endothelial cell growth
AU2005227313A1 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
NZ551335A (en) * 2004-06-18 2010-03-26 Ambrx Inc Antibodies and fragments thereof comprising an non naturally encoded amino acid coupled to a linker
KR20070039593A (en) * 2004-07-21 2007-04-12 암브룩스, 인코포레이티드 Biosynthetic polypeptides utilizing non-naturally encoded amino acids
WO2006023603A2 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
NZ554142A (en) 2004-10-06 2009-12-24 Agri Biotech Pty Ltd Antibody production method comprising inserting antigen releasing device into mammal so antibodies are released into its milk
WO2006055638A2 (en) 2004-11-17 2006-05-26 Abgenix, Inc. Fully human monoclonal antibodies to il-13
DE602005027399D1 (en) 2004-12-20 2011-05-19 Amgen Fremont Inc For human matriptase specific tie proteins
MX2007007484A (en) 2004-12-21 2007-07-20 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof.
WO2006069246A2 (en) 2004-12-22 2006-06-29 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (en) * 2004-12-22 2009-02-10 Ambrx Inc modified human growth hormone
KR20070100299A (en) 2004-12-22 2007-10-10 암브룩스, 인코포레이티드 Methods for expression and purification of recombinant human growth hormone
BRPI0519170A8 (en) * 2004-12-22 2018-05-08 Ambrx Inc human growth hormone formulations comprising an unnaturally encoded amino acid
NZ555425A (en) * 2004-12-22 2010-04-30 Ambrx Inc Compositions of aminoacyl-tRNA synthetase and uses thereof
EP2361933A3 (en) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antibodies against interleukin-1 beta
CN101247821B (en) * 2005-06-03 2013-01-23 Ambrx公司 Improved human interferon molecules and their uses
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
AT446972T (en) 2005-06-21 2009-11-15 Xoma Technology Ltd Il-1 binding antibodies and fragments thereof
EP1909812A4 (en) 2005-07-27 2009-11-25 Univ Florida Small compounds that correct protein misfolding and uses thereof
AU2005335491B2 (en) * 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
US20090137736A1 (en) * 2005-11-08 2009-05-28 Ambrx, Inc. Accelerants for the Modification of Non-Natural Amino Acids and Non-Natural Amino Acid Polypeptides
EP2548583A3 (en) 2005-11-10 2013-02-27 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
AU2006315347A1 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
US8158588B2 (en) 2005-12-05 2012-04-17 Simon Delagrave Loop-variant PDZ domains as biotherapeutics, diagnostics and research reagents
EP1979001B1 (en) 2005-12-13 2012-04-11 Medimmune Limited Binding proteins specific for insulin-like growth factors and uses thereof
AT480559T (en) 2005-12-14 2010-09-15 Licentia Ltd Uses of a neurotrophic factor
CA2882445A1 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0619853A2 (en) 2005-12-15 2016-08-23 Astrazeneca Ab combination, pharmaceutical composition, and methods of antagonizing biological activity, treating disease-related angiogenesis in a mammal, and treating cancer in a mammal
EP1973942B1 (en) 2005-12-22 2011-02-09 Genentech, Inc. Recombinant production of heparin binding proteins
BRPI0620819A2 (en) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd use of a sustained release neuregulin (nrg), nrg at a sustained release from a constant low dosage, and, sustained release composition to prevent, treat or delay a disease or disorder in a mammal
JP4923625B2 (en) * 2006-03-01 2012-04-25 パナソニック株式会社 rice cooker
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2049570B1 (en) 2006-06-01 2016-08-10 President and Fellows of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
EP2054437A2 (en) 2006-08-07 2009-05-06 Teva Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CN106008699A (en) * 2006-09-08 2016-10-12 Ambrx公司 Modified human plasma polypeptide or Fc scaffolds and their uses
US9133495B2 (en) * 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
JP5451390B2 (en) * 2006-09-08 2014-03-26 アンブルックス,インコーポレイテッドAmbrx,Inc. Transcription of suppressor TRNA in vertebrate cells
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
TWI428346B (en) 2006-12-13 2014-03-01 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
MX2009006709A (en) 2006-12-20 2009-07-02 Xoma Technology Ltd Methods for the treatment of il-1ã¿ related diseases.
PL2068909T3 (en) * 2007-03-30 2012-09-28 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
JP2010525821A (en) * 2007-05-02 2010-07-29 アンブルックス,インコーポレイテッドAmbrx,Inc. Modified IFN beta polypeptides and their use
WO2008140026A1 (en) 2007-05-11 2008-11-20 Bizen Chemical Co., Ltd. Novel leukotriene receptor antagonist
CA2691166A1 (en) 2007-06-27 2008-12-31 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2040075A1 (en) 2007-09-24 2009-03-25 Julius-Maximilians-Universität Würzburg Compounds and markers for surface-enhanced raman scattering
US8828382B2 (en) 2007-09-26 2014-09-09 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor binding proteins
KR101656107B1 (en) * 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 Modified insulin polypeptides and their uses
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
MX2010008632A (en) 2008-02-08 2010-08-30 Ambrx Inc Modified leptin polypeptides and their uses.
FI20080326A0 (en) 2008-04-30 2008-04-30 Licentia Oy Neurotrophic factor MANF and its uses
ES2714453T3 (en) 2008-06-09 2019-05-28 Ludwig Maximilians Univ Muenchen Drugs to inhibit the aggregation of proteins involved in diseases related to neurodegenerative diseases and / or aggregation of proteins
KR101726884B1 (en) 2008-07-23 2017-04-26 암브룩스, 인코포레이티드 Modified bovine g-csf polypeptides and their uses
CN102177438A (en) 2008-07-25 2011-09-07 X博迪生物科学公司 Protein screeing methods
WO2010030813A2 (en) 2008-09-10 2010-03-18 Genentech, Inc. Methods for inhibiting ocular angiogenesis
US8192738B2 (en) 2008-09-19 2012-06-05 Medimmune, Llc Targeted antibodies directed to DLL4
CN102232085A (en) 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
NZ592249A (en) 2008-09-26 2013-03-28 Ambrx Inc Non-natural amino acid replication-dependent microorganisms and vaccines
EP2382235B1 (en) 2008-12-19 2016-02-24 Christiane Hilger Novel caviidae allergen and uses thereof
US20110312872A1 (en) 2008-12-22 2011-12-22 Universität Regensburg Norrin in the treatment of diseases associated with an increased tgf-beta activity
JP2012513194A (en) 2008-12-23 2012-06-14 アストラゼネカ アクチボラグ Targeted binding agents directed to α5β1 and uses thereof
KR101040396B1 (en) 2009-01-20 2011-06-09 한올바이오파마주식회사 Modified human thrombopoietin polypeptide fragment and method for preparing the same
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US20110014190A1 (en) 2009-02-12 2011-01-20 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
CA2751831A1 (en) 2009-02-13 2010-08-19 Novartis Ag Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
DK2442644T3 (en) 2009-06-16 2016-10-10 Bikam Pharmaceuticals Inc Opsin-binding ligands, COMPOSITIONS AND METHODS FOR USE
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
EP2305810A1 (en) 2009-10-02 2011-04-06 Technische Universität München miRNAs in the treatment of fibrosis
CN102711772A (en) 2009-10-16 2012-10-03 奥克兰联合服务有限公司 Anti-neoplastic uses of artemin antagonists
US8729058B2 (en) 2009-10-27 2014-05-20 Michael Zasloff Methods and compositions for treating and preventing viral infections
EP2504364B1 (en) 2009-11-24 2017-08-09 Medimmune Limited Targeted binding agents against b7-h1
WO2011066260A2 (en) 2009-11-25 2011-06-03 Michael Zasloff Formulations comprising aminosterols
PE20121707A1 (en) 2009-12-21 2012-12-17 Ambrx Inc Modified bovine somatotropin polypeptides and their uses
EA201290542A1 (en) 2009-12-21 2013-07-30 Амбркс, Инк. Modified pork somatotropine polypeptides and their application
EP2525792A1 (en) 2010-01-19 2012-11-28 Medizinische Universität Wien Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
AU2011210825B2 (en) 2010-01-27 2017-02-02 Children's Medical Center Corporation Pro-angiogenic fragments of prominin-1 and uses thereof
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
WO2011131626A1 (en) 2010-04-19 2011-10-27 Medizinische Universität Innsbruck Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
EP2566964B1 (en) 2010-05-07 2016-10-19 Centre National De La Recherche Scientifique Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
EP2582720B1 (en) 2010-06-18 2014-05-21 XiberScience GmbH Peptides as active agents to stabilize biological barriers
JP6054294B2 (en) 2010-08-17 2016-12-27 アンブルックス,インコーポレイテッドAmbrx,Inc. Modified relaxin polypeptides and uses thereof
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
PT2667715T (en) 2011-01-27 2017-10-19 Neuren Pharmaceuticals Ltd Treatment of autism spectrum disorders using glycyl-l-2-methylprolyl-l-glutamic acid
KR20140021594A (en) 2011-03-10 2014-02-20 제넨테크, 인크. Treatment of disorders with altered vascular barrier function
EA026121B1 (en) 2011-06-14 2017-03-31 Бикам Фармасьютикалз, Инк. Opsin-binding ligands, compositions and methods of use thereof
WO2013017656A1 (en) 2011-08-02 2013-02-07 Medizinische Universität Wien Antagonists of ribonucleases for treating obesity
EP2745113B1 (en) 2011-08-16 2017-03-22 Evotec (München) GmbH Markers for susceptibility to an inhibitor of an src-family kinase
US20140314667A1 (en) 2011-11-16 2014-10-23 Amgen Inc. Methods of treating epidermal growth factor deletion mutant viii related disorders
EP2785346A4 (en) 2011-11-30 2015-04-29 Bikam Pharmaceuticals Inc Opsin-binding ligands, compositions and methods of use
EP2601941A1 (en) 2011-12-06 2013-06-12 Ludwig-Maximilians-Universität München Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
WO2013106489A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
EP2802603A4 (en) 2012-01-09 2015-11-04 Scripps Research Inst Ultralong complementarity determining regions and uses thereof
EP2626066A1 (en) 2012-02-10 2013-08-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2014006063A2 (en) 2012-07-02 2014-01-09 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
EP2687225A1 (en) 2012-07-19 2014-01-22 Alfact Innovation HIP/PAP protein and derivatives thereof for use in treating cancer
EP2695950A1 (en) 2012-08-10 2014-02-12 Blackfield AG Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
JP2015526471A (en) 2012-08-21 2015-09-10 ジェネシス リサーチ インスティチュート Compositions and methods for treating or preventing anthracycline-induced cardiotoxicity
EP2926142B1 (en) 2012-11-30 2018-11-07 F.Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
EP2999797B1 (en) 2013-05-21 2018-07-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
WO2014191630A2 (en) 2013-05-28 2014-12-04 Helsingin Yliopisto Non-human animal model encoding a non-functional manf gene
EP2810648A1 (en) 2013-06-04 2014-12-10 Daniel Rauh Targeting domain-domain interaction for the identification of kinase modulators
EP2835135A3 (en) 2013-06-19 2015-06-24 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Means and methods for treating pseudomonas infection
WO2014207213A1 (en) 2013-06-28 2014-12-31 Medizinische Universität Innsbruck Novel inhibitors of protein kinase c epsilon signaling
WO2015010100A2 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015022326A1 (en) 2013-08-12 2015-02-19 Xiber Science Gmbh Peptides as active agents for treating primary graft dysfunction
US9371570B2 (en) 2013-09-16 2016-06-21 CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH Mutant calreticulin for the diagnosis of myeloid malignancies
AU2014337367A1 (en) 2013-10-15 2016-04-07 The Scripps Research Institute Peptidic chimeric antigen receptor T cell switches and uses thereof
CA2926698A1 (en) 2013-10-15 2015-04-23 The California Institute For Biomedical Research Chimeric antigen receptor t cell switches and uses thereof
GB201319374D0 (en) 2013-11-01 2013-12-18 Univ Nottingham Glycans as functional cancer targets abd antibodies thereto
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
WO2015173398A1 (en) 2014-05-15 2015-11-19 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of slc38a9 and their use in therapy
EP2947460A1 (en) 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
MX2017004947A (en) 2014-10-24 2017-06-29 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof.
WO2016079321A1 (en) 2014-11-20 2016-05-26 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Antagonists of setdb2 for use in the therapy of infectious diseases
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
JP2018506994A (en) 2015-02-23 2018-03-15 シーガル セラピューティクス エスアーエス Non-natural semaphorins 3 and their medical use
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016170102A1 (en) 2015-04-22 2016-10-27 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of an antiandrogen with a vitamin k antagonist or with a gamma -glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
CA3004680A1 (en) 2015-11-13 2017-05-18 Mavalon Therapeutics Limited Substituted tricyclic 1,4-benzodiazepinone derivatives as allosteric modulators of group ii metabotropic glutamate receptors
CN108368143A (en) 2015-12-09 2018-08-03 维也纳医科大学 The maleimide-functionalised platinum compounds of list for cancer therapy
JP2019508383A (en) 2016-01-15 2019-03-28 ウニベルジテート ハンブルグUniversitaet Hamburg Flavonoid-type compound having O-rhamnosyl residue
WO2017140728A1 (en) 2016-02-15 2017-08-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Taf1 inhibitors for the therapy of cancer
EP3216458A1 (en) 2016-03-07 2017-09-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified vascular endothelial growth factor a (vegf-a) and its medical use
EP3493848A1 (en) 2016-08-02 2019-06-12 Friedrich-Alexander-Universität Erlangen-Nürnberg Heterocyclic diamidines
AU2017345479A1 (en) 2016-10-19 2019-05-09 The Scripps Research Institute Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
WO2018087401A2 (en) 2016-11-14 2018-05-17 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
WO2018099952A1 (en) 2016-11-30 2018-06-07 Oncotyrol Center For Personalized Cancer Medicine Gmbh 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors
CA3052639A1 (en) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2018265615A1 (en) 2017-05-12 2019-10-03 Mavalon Therapeutics Limited Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors
WO2018206778A1 (en) 2017-05-12 2018-11-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
WO2019110139A1 (en) 2017-12-05 2019-06-13 Eth Zurich New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
WO2019193159A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of hyperhidrosis
WO2019193161A1 (en) 2018-04-06 2019-10-10 Universität Wien Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
WO2019207051A1 (en) 2018-04-25 2019-10-31 Università Degli Studi Di Torino Medical use of combinations of non-natural semaphorins 3 and antimetabolites

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029762A (en) * 1971-11-17 1977-06-14 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Lipid A-preparation
WO1983003383A1 (en) * 1982-03-29 1983-10-13 Liposome Co Inc Stable plurilamellar vesicles

Also Published As

Publication number Publication date
EP0142641A3 (en) 1985-08-14
DE3486459D1 (en) 1997-12-11
KR850002402A (en) 1985-05-13
JPS60155123A (en) 1985-08-15
AT159858T (en) 1997-11-15
AU560178B2 (en) 1987-04-02
HK93191A (en) 1991-11-29
EP0142641A2 (en) 1985-05-29
JPH0577658B2 (en) 1993-10-27
DK455384A (en) 1985-03-27
AU3332784A (en) 1985-04-04
DK168755B1 (en) 1994-06-06
DE3483949D1 (en) 1991-02-21
KR910005408B1 (en) 1991-07-29
EP0350973A1 (en) 1990-01-17
EP0350973B1 (en) 1997-11-05
CA1234754A (en) 1988-04-05
DD222783A5 (en) 1985-05-29
CA1234754A1 (en)
US5021234A (en) 1991-06-04
DK455384D0 (en) 1984-09-24
EP0142641B1 (en) 1991-01-16

Similar Documents

Publication Publication Date Title
DE68905846D1 (en) Saturated leach for treatment of wells and additive for it.
DE2856393A1 (en) Agents for the treatment of central nervous system
DE3587296D1 (en) Drugs and method for its manufacture and application to tumor treatment.
ITMI912687A1 (en) Set of diagnostic elements to diagnose and distinguish the chest pain at the first onset.
DE68902649T2 (en) Locally applicable pharmaceutical preparation for treatment of entzuendungserkrankungen.
DE68922319T2 (en) Bioabsorbable surgical material for the treatment of nerve defects and method for its preparation.
AT31625T (en) A pharmaceutical agent for the treatment of diabetes mellitus.
DE3889082T2 (en) Treatment and after-treatment of metals by Kohlenstoffhydratmodifizierten polyphenol compounds.
DE2834741A1 (en) geraet cryosurgical and method for killing of human tissue or the like.
NO983183L (en) Compositions and methods for treatment and diagnosis of breast cancer
DE3855489T2 (en) Treatment of skin wrinkles
DE3752141D1 (en) Means for treatment of neuropathy
DE69329112T2 (en) Intraoperative, intravascular and endoscopic determination and treatment of tumors and injuries
DE318216T1 (en) NANBV diagnostic agents and vaccines.
NO890224L (en) Method and apparatus for medical treatment of the pathological condition of bone.
AT109968T (en) Oral agents for the treatment of hypersensitivity of the teeth.
AT126441T (en) Pentigetide diseases for treatment of non-IgE mediated inflammatory.
DE69400635T2 (en) Hautbefeuchtendes means for the simultaneous treatment of upper and deeper layers of the skin as well as their use
DE3579343D1 (en) Means for treatment and protect the skin.
DE69400338T2 (en) Depigmentierendes means for the simultaneous treatment of skin upper layers and deep layers of the skin
DE69528653T2 (en) Genetic diagnosis and pharmaceutical products for the treatment of prostate cancer
AT96033T (en) Means for treatment of osteoarthritis.
DE68928665T2 (en) Treatment of gastrointestinal diseases
DE69027024T2 (en) Matritzenmetalloproteinasepeptide their effective in diagnosis and therapy
DE3579113D1 (en) Compositions for the alleviation, treatment and bestimmungung arthritschen of diseases and related conditions.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee